KRAS and cancer: In addition to the GSK-3β up-regulation of the NF-κB pathway, which has a broad pro-cancer effect, GSK-3β is also involved in another major pro-cancer pathway in PDAC, namely the k-ras pathway, which is activated in 95% of PDAC patients.